长效干扰素在费城染色体阴性骨髓增殖性肿瘤中的研究进展  

Progress of long-acting interferon in Philadelphia chromosome-negative myloproliferative neoplasms

作　　者：王彬彬 唐古生 Wang Binbin;Tang Gusheng(Department of Hematology,the First Affiliated Hospital of Navy Medical University,Shanghai 200433,China)

机构地区：[1]海军军医大学第一附属医院血液内科,上海200433

出　　处：《白血病．淋巴瘤》2023年第10期628-630,共3页Journal of Leukemia & Lymphoma

基　　金：上海市自然科学基金(20ZR1457000);海军军医大学第一附属医院自由探索项目(2020SLZ022)。

摘　　要：费城染色体阴性骨髓增殖性肿瘤(MPN),是一类由造血干细胞克隆性增生引起的慢性血液系统肿瘤,羟基脲为传统的一线化疗药物。近年来,聚乙二醇干扰素在MPN治疗实践中体现出较大的优势,已经成为年轻患者及妊娠期妇女等特殊人群治疗的一线优选方案。Philadelphia chromosome-negative myeloproliferative neoplasms(MPN)is a group of chronic hematological tumors caused by clonal proliferation of hematopoietic stem cells,and hydroxyurea is the traditional first-line chemotherapy drug for it.In recent years,pegylated interferon has shown great advantages in the clinical treatment of MPN,and it has become the first-line preferred therapeutic regimen for special populations,especially for young patients and pregnant women.

关 键 词：骨髓增殖性肿瘤 干扰素 分子学反应率 

分 类 号：R733.3[医药卫生—肿瘤]